Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
400 mg intravenously every 8-12 hours over 60 minutes.
Otic suspension: 3 drops (0.25 mL) into affected ear(s) twice daily for 7 days. Each drop contains ciprofloxacin HCl (equivalent to 0.2 mg ciprofloxacin base) and hydrocortisone 1 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Ciprofloxacin: ~4-5 hours (normal renal function); prolonged to 8-10 hours in severe renal impairment (CrCl <30 mL/min). Hydrocortisone: ~1.5-2 hours.
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Ciprofloxacin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; ~15-20% as metabolites; ~20-30% in feces via biliary excretion and transintestinal secretion. Hydrocortisone: metabolized in liver, metabolites excreted renally.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic